Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients

Respirology

Volumn 21, Issue 8, 2016, Pages 1411-1418

  Gudiol, Carlota ^a,c   Royo Cebrecos, Cristina ^a,c   Laporte, Júlia ^a   Ardanuy, Carmen ^b,c   Garcia Vidal, Carolina ^a,c   Antonio, Maite ^a   Arnan, Montserrat ^a   Carratalà, Jordi ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

bacteraemic pneumonia; bloodstream infection; cancer; neutropenia; pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ADULT; ADVANCED CANCER; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACILLUS CEREUS; BACTERIAL PNEUMONIA; CANCER PATIENT; CASE FATALITY RATE; CLINICAL FEATURE; ESCHERICHIA COLI; FEMALE; GRAFT RECIPIENT; HAEMOPHILUS INFLUENZAE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORGANELLA MORGANII; MULTIDRUG RESISTANCE; NEISSERIA ELONGATA; NEUTROPENIA; NEUTROPENIC CANCER PATIENT; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RISK FACTOR; SEROTYPE; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS MITIS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SANGUINIS; BACTEREMIA; BLOOD; COMPLICATION; DISEASE MANAGEMENT; HOSPITALIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NEEDS ASSESSMENT; NEOPLASM; RETROSPECTIVE STUDY; SPAIN; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AGED; BACTEREMIA; DISEASE MANAGEMENT; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEEDS ASSESSMENT; NEOPLASMS; NEUTROPENIA; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 84991487872     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12848     Document Type: Article

References (32)

1. th century: a period analysis. Lancet 2002; 360: 1131–5.
2. Rossini F, Verga M, Pioltelli P, Giltri G, Sancassani V, Pogliani EM, Corneo G. Incidence and outcome of pneumonia in patients with acute leukemia receiving first induction therapy with anthracycline containing regimens. Haematologica 2000; 85: 1255–60.
3. Meyer E, Beyersmann J, Bertz H, Wenzler-Röttele S, Babikir R, Schumacher M, Daschner FD, Rüden H, Dettenkofer M, ONKO-KISS Study Group. Risk factor analysis of bloodstream infection and pneumonia in neutropenic patients after peripheral blood stem-cell transplantation. Bone Marrow Transplant. 2007; 139: 173–8.
4. Yoshida M, Akiyama N, Fujita H, Miura K, Miyatake J, Handa H, Kito K, Takahashi M, Shigeno K, Kanda Y et al. Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. Int. J. Hematol. 2011; 93: 66–73.
5. Evans SE, Ost DE. Pneumonia in the neutropenic cancer patients. Curr. Opin. Pulm. Med. 2015; 21: 260–71.
6. Lanoix JP, Schmit JL, Douadi Y. Bacterial lung sepsis in patients with febrile neutropenia. Curr. Opin. Pulm. Med. 2012; 18: 175–80.
7. Dettenkofer M, Wenzler-Rötelle S, Babikir R, Bertz H, Ebner W, Meyer E, Rüden H, Gastmeier P, Daschner FD, Hospital Infection Surveillance System for Patients with Hematologic/Oncologic Malignancies Study Group. Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant: a multicenter project. Clin. Infect. Dis. 2005; 40: 926–31.
8. Chen CS, Boeckh M, Seidel K, Clark JG, Kansu E, Madtes DK, Wagner JL, Witherspoon RP, Anasetti C, Appelbaum FR et al. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003; 32: 515–22.
9. Aguilar-Guisado M, Jiménez-Jambrina M, Espigado I, Rovira M, Martino R, Oriol A, Borrell N, Ruiz I, Martín-Dávila P, de la Cámara R et al. Spanish Network for Research in Infectious Diseases. Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study. Clin. Transplant. 2011; 25: E629–38.
10. Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M, Domingo-Domenech E, Jiménez L, Carratalà J. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin. Microbiol. Infect. 2013; 19: 474–9.
11. Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, Akova M, Fourth European Conference on Infections in Leukemia Group (ECIL-4), a joint venture of EBMT, EORTC, ICHS, ELN and ESGICH/ESCMID. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J. Infect. 2014; 68: 321–31.
12. Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta-lactam antibiotic monotherapy versus beta-lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst. Rev. 2014; 1: CD003344.
13. Klastersky J, Paesmans M, Ruberstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K et al. The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J. Clin. Oncol. 2000; 18: 3038–51.
14. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012; 18: 268–81.
15. The European Committee on Antimicrobial Susceptibility Testing. Breakpoints tables for interpretation of MICs and zone diameters. Version 5.0, 2015. Available from URL: http://www.eucast.org.
16. Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, Costa LJ. Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant. 2011; 17: 1176–81.
17. Carratalà J, Roson B, Fernández-Sevilla A, Alcaide A, Gudiol F. Bacteremic pneumonia in neutropenic patients with cancer. Arch. Intern. Med. 1998; 158: 868–72.
18. Frankard J, Li R, Taccone F, Struelens MJ, Jacobs F, Kentos A. Bacillus cereus pneumonia in a patient with acute lymphoblastic leukemia. Eur. J. Clin. Microbiol. Infect. Dis. 2004; 23: 725–8.
19. Azoulay E, Soares M, Darmon M, Benoit D, Pastores S, Afessa B. Intensive care of the cancer patient: recent achievements and remaining challenges. Ann. Intensive Care 2011; 1: 5.
20. Soares M, Caruso P, Silva E, Teles JM, Lobo SM, Friedman G, Dal Pizzol F, Mello PV, Bozza FA, Silva UV et al. Brazilian Research in Intensive Care Network (BRICNet). Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study. Crit. Care Med. 2010; 38: 9–15.
21. Regazzoni CJ, Irrazabal C, Luna CM, Poderoso JJ. Cancer patients with septic shock: mortality predictors and neutropenia. Support. Care Cancer 2004; 12: 833–9.
22. Rabello LS, Silva JR, Azevedo LC, Souza I, Torres VB, Rosolem MM, Lisboa T, Soares M, Salluh JI. Clinical outcomes and microbiological characteristics of severe pneumonia in cancer patients: a prospective cohort study. PLoS One 2015; 10: e0120544.
23. de Montmollin E, Tandjaoui-Lambiotte Y, Legrand M, Lambert J, Mokart D, Kouatchet A, Lemiale V, Pène F, Bruneel F, Vincent F et al. Outcomes in critically ill cancer patients with septic shock of pulmonary origin. Shock 2013; 39: 250–4.
24. Song JU, Suh GY, Park HY, Lim SY, Han SG, Kang YR, Kwon OJ, Woo S, Jeon K. Early intervention on the outcomes in critically ill cancer patients admitted to intensive care units. Intensive Care Med. 2012; 38: 1505–13.
25. Azoulay E, Thiery G, Chevret S, Moreau D, Darmon M, Bergeron A, Yang K, Meignin V, Ciroldi M, Le Gall JR et al. The prognosis of acute respiratory failure in critically ill cancer patients. Medicine 2004; 83: 360–70.
26. Gristina GR, Antonelli M, Conti G, Ciarlone A, Rogante S, Rossi C, Bertolini G, GiViTI (Italian Group for the Evaluation of Interventions in Intensive Care Medicine). Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: a 5-year multicenter observational survey. Crit. Care Med. 2011; 39: 2232–9.
27. Lemiale V, Mokart D, Resche-Rigon M, Pène F, Mayaux J, Faucher E, Nyunga M, Girault C, Perez P, Guitton C et al. Groupe de Recherche en Réanimation Respiratoire du patient d'Onco-Hématologie (GRRR-OH). Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA. 2015; 314: 1711–9.
28. Peters SG, Holets SR, Gay PC. High-flow nasal cannula therapy in do-not intubate patients with hypoxemic respiratory distress. Respir. Care 2013; 58: 597–600.
29. Tramm R, Ilic D, Davies AR, Pellegrino VA, Romero L, Hodgson C. Extracorporeal membrane oxygenation for critically ill adults. Cochrane Database Syst. Rev. 2015; 1: CD010381.
30. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2011; 52: 427–31.
31. th European Conference on Infections in Leukemia. Haematologica 2013; 98: 1826–35.
32. Maschmeyer G, Carratalà J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, Ruhnke M et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann. Oncol. 2015; 26: 21–33.